<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bittner, Dennis</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Holsboer, Florian</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">New Approaches Required in Drug Development Process for Antidepressants</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-08-11 13:08:33</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">Florian Holsboer, director of the Max-Planck Institute for Psychiatry for 25 years, called for a reengineering of the drug development process for antidepressants, meaning a shift from a focus on blockbuster drugs capable of treating all depression to use of biomarkers to target subsets of patients based on disease etiology.</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>